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The mismatched minor histocompatibility antigens present on Y chromosome (H-Y) in male recipients
receiving stem cells from female donors may contribute to the graft-versus-leukemia effect and results in a
reduced relapse rate, especially in patients with high-risk disease. We retrospectively compared the outcomes
of male patients with acute myeloid leukemia who received an allogeneic hematopoietic stem cell transplant
(HSCT) from female donors (F-M) (174 patients) versus other gender combinations (667 patients). Median age
was 50 years (range, 18 to 74 years). For the whole group, the 1-year cumulative incidence of relapse was
signiﬁcantly lower in F-M group (34.1% versus 41.3%, P ¼ .044), whereas nonrelapse mortality (NRM) was
higher (23.2% versus 15.7%, P ¼ .004). For patients younger than 50 years beyond ﬁrst complete remission, the
F-M group was associated with lower relapse rate (42.5% versus 55.2%, P ¼ .045) whereas NRM was not
signiﬁcantly different (35.8% versus 25.5%, P ¼ .141). Although survival was not signiﬁcantly improved,
transplantation from a female donor for male recipient was associated with a lower relapse rate. When
relapse is the most common concern for treatment failure, especially for younger patients, a female donor for
a male recipient might be beneﬁcial to decrease relapse rate after transplantation. Future studies are needed
to explore how the H-Y mismatch may improve survival after transplantation.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic hematopoietic stem cell transplantation
(HSCT) represents a potentially curative therapy for patients
with acute myeloid leukemia (AML) and other hematolo-
gic malignancies. The efﬁcacy of transplantation against
leukemic cells is the result of both conditioning che-
motherapy and graft-versus-leukemia (GVL) effect, which is
induced primarily by the minor histocompatibility antigens
(miHA) present on the surface of leukemic cells [1,2].
Unfortunately, as some of these antigens are also expressed
on the recipient’s nonhematopoietic cells, alloreactivity
against the recipient’s tissues can lead to a potential fatal
complication, graft-versus-host disease (GVHD). One of
the miHA associated with GVL and GVHD is a group of Y
chromosomeeencoded proteins (H-Y) in male recipients,ledgments on page 719.
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ty for Blood and Marrow Transplantation.which may be recognized by T lymphocytes from female
donors in the setting of a gender-mismatched trans-
plantation. The stronger alloreactivity effect of the donor-
recipient gender-mismatched HSCT was ﬁrst described in
the patients with aplastic anemia. Storb et al. reported the
higher transplantation-related mortality and incidence of
GVHD in aplastic anemia patients who received a gender-
mismatched transplant, compared with gender-matched
transplant recipients [3]. Later, several studies demon-
strated that HSCT from female donors to male recipients
(F-M), compared with all other donor-recipient gender
combinations, was associated with a lower relapse rate in
patients with hematologic malignancies [4-6]. However,
whether or not there is an advantage of a stronger GVL effect
in gender-mismatched transplantation, in particular using
female donors for male recipients, remains unclear because
of conﬂicting reports published to date [4-7]. Moreover, no
data exist for AML patients. Younger patients may have lower
treatment-related mortality and be able to better tolerate
GVHD; thus, we hypothesized that such patients might
P. Kongtim et al. / Biol Blood Marrow Transplant 21 (2015) 713e719714beneﬁt from a stronger antitumor effect generated by using a
female donor instead of the traditional male donor, when
this option is available. We retrospectively analyzed the
impact of donor-recipient gender mismatch on trans-
plantation outcomes in a uniform large cohort of AML
patients treated with busulfan-based conditioning and a
matched donor at our institution.
PATIENTS AND METHODS
We analyzed transplantation outcomes of all 841 patients, 18 years or
older (456 male, 385 female) with a diagnosis of AML who received their
ﬁrst transplant from an HLA-matched related (MRD) or 8/8 matched unre-
lated donor (MUD) at The University of Texas MD Anderson Cancer Center
between January 1991 and June 2012. Clinical data were gathered at the
time of transplantation. The median interval from diagnosis to trans-
plantation was 8 months (range, 1 to 332 months); 453 (53.9%) and 388
patients (46.1%) received transplants from MRD and MUD, respectively.
All patients received a uniform conditioning regimen with ﬂudarabine
and busulfan, as previously reported by our group [8,9]. The great majority
of patients received myeloablative conditioning (MAC) (93.7%), whereas 53
patients (6.3%) received a reduced-intensity conditioning regimen (RIC)
with lower busulfan doses (area under the curve of 4000/day or less). Most
frequent GVHD prophylaxis regimen was combined tacrolimus and meth-
otrexate (n¼ 774, 92%). Patients were categorized into 2 groups according to
donor-recipient gender combinations: female donor to male recipient (F-M)
(n ¼ 174) and other gender combinations (OGC) (n ¼ 667).
The primary endpoints were progression-free survival (PFS), overall
survival (OS), cumulative incidence of relapse (CIR), nonrelapse mortality
(NRM), and acute and chronic GVHD. All outcomes were measured from the
time of stem cell infusion. The date of neutrophil engraftment was deﬁned
as the ﬁrst day of granulocyte counts greater than .5  109/L for 3 consec-
utive days, derived at least in part from donor cells. The date of platelet
engraftment was deﬁned as the ﬁrst day of platelet counts greater than
20,000/L for 7 consecutive days independent of transfusions. PFS was
deﬁned as the time between HSCT and disease relapse or death from any
cause; data for patients who were alive without relapse was censored at the
date of last contact. OS was deﬁned as the time between HSCT and death
from any cause; surviving patients were censored at the date of last contact.
Relapse was deﬁned as hematologic recurrence of AML according to World
Health Organization criteria [10]. NRMwas deﬁned as death related to HSCT
during continuous remission. OS and PFS were calculated using the Kaplan-
Meier method. Univariate comparisons of all endpoints were completed by
the log-rank test. Cumulative incidence was used to estimate the endpoints
of relapse, NRM, acute GVHD, and chronic GVHD. A Cox proportion hazards
model [11] or the Fine and Gray method [12] for competing hazards were
used for multivariate regression. Variables were included in the multivariate
models if they were conceptually important or if they approached (P < .10)
or attained statistical signiﬁcance in the univariate regression. All factors
were tested for the proportional hazards assumption. Analyses were per-
formed using SPSS statistics program for Mac OS version 20.0.
The institutional review board of the MD Anderson Cancer Center
approved the treatment protocols and this retrospective study. All patients
provided written informed consent for transplantation according to the
Declaration of Helsinki.
RESULTS
Patients’ characteristics are listed in Table 1. The median
age was 50 years (range, 18 to 74 years). All 841 patients had
de novo AML, except for 146 (17.3%) who had secondary or
therapy-related AML. Two hundred and ninety-eight pa-
tients (35.4%) had high-risk cytogenetics at diagnosis ac-
cording to the Medical Research Council (MRC) cytogenetic
classiﬁcation [13] and 561 patients (66.7%) were in remission
before transplantation. Cytogenetics and molecular data ac-
cording to the European Leukemia Net (ELN) classiﬁcation
[14] could be evaluated in 621 patients (252 patients were in
adverse ELN risk group). There were no signiﬁcant differ-
ences in baseline characteristics between the F-M and OGC
groups, except there were more patients with secondary
AML in the F-M group (22.9% versus 16.4%; P ¼ .018). Sixty-
one patients (35.1%) in the F-M group and 237 patients
(35.5%) in the OGC group had high-risk cytogenetic accord-
ing to MRC classiﬁcation (P ¼ .652). Fifty-three patients(30.4%) in the F-M group and 227 patients (34%) in the OGC
group underwent transplantation with active disease
(P ¼ .479). Eight hundred and eighteen patients (97.3%)
engrafted the donor cells (96% in F-M group and 97.6% in OGC
group, P ¼ .397) with a median time to neutrophil and
platelet engraftment of 12 days and 13 days, respectively.
There was no signiﬁcant difference in time to neutrophil and
platelet engraftment between the F-M and OGC groups (P ¼
.57). At the time of last follow-up, 387 (46%) patients were
alive, withmedian follow-up duration of 35months (range, 3
to 241 months). Transplantation outcomes are summarized
in Table 2.
Relapse
The CIR at 1 year for the entire cohort was 39.9%. When
compared with patients in the OGC group patients in F-M
group had a lower relapse rate, with a CIR at 1 year of 34.1%
versus 41.3% in OGC group (P ¼ .044) (Supplemental Figure
1). This difference was related to a signiﬁcantly lower relapse
rate for patients beyond ﬁrst complete remission (CR) before
transplantation, with a 1-year CIR of 39.8% in the F-M group
versus 52% in the OGC group (P¼ .039) (Supplemental Figure
2), whereas patients who underwent HSCT in ﬁrst CR had
similar CIR (27.7% in F-M group, 31.2% in OGC, P ¼ .419)
(Supplemental Figure 3). We then analyzed the CIR of a
subgroup of the patients who were not in ﬁrst CR and
younger than 50 years to see whether using a female donor
for a male recipient had a beneﬁt in younger patients with
high-risk disease. In this age group, we have also found a
signiﬁcantly lower CIR in the F-M group (42.5%) compared
with the OGC group (55.2%) (P¼ .045) (Figure 1A). Outcomes
of F-M compared with OGC group stratiﬁed by age, donor-
recipient race matching, disease characteristics and status,
conditioning regimens, stem cell sources, and HSCT types are
summarized in Table 3. The beneﬁt of using a female donor
for a male recipient in lowering the rate of relapse was also
seen in subgroup of patients who were younger than
50 years, not in remission before transplantation, received
myeloablative conditioning, received peripheral blood stem
cells, and from an MRD. Beside donor-recipient gender
combinations, other factors associated with increased risk of
relapse in univariate analyses were high-risk cytogenetics,
adverse ELN risk, disease beyond ﬁrst CR at transplantation,
transplantation using RIC, and the presence of mixed donor-
recipient chimerism early after transplantation, whereas
having chronic GVHD was associated with a lower relapse
rate (Table 4). All of these factors retained statistical signiﬁ-
cance in multivariate regression analysis (Table 5). In addi-
tion, using a female donor for a male recipient was an
independent prognostic factor for lower relapse, with hazard
ratio of .71 (95% conﬁdence interval, .47 to .91; P ¼ .04).
NRM
NRM at 1 year of the whole cohort was 17%. According to
donor-recipient gender combinations, patients in F-M group
had signiﬁcantly higher NRM compared with those in the
OGC group, with 1-year NRM of 23.2% versus 15.7%, respec-
tively (P ¼ .004) (Supplemental Figure 4). When compared
with the OGC, F-M group had higher incidence of fatal acute
GVHD (8.5% versus 2.3%, P¼ .031), chronic GVHD (7.1% versus
1.4%, P ¼ .027), and death from infections (11.6% versus 2.4%,
P ¼ .025).
Again, the statistical signiﬁcance was seen in subgroup
patients who were not in ﬁrst CR before HSCT (29.1% in F-M
group versus 17.4% in OGC group, P ¼ .004) (Supplemental
Table 1
Patient and Transplantation Characteristics
Characteristic All Patients First CR Beyond First CR Beyond First CR, < 50 Years
F-M (n ¼ 174) OGC (n ¼ 667) P Value F-M (n ¼ 89) OGC (n ¼ 334) P Value F-M (n ¼ 81) OGC (n ¼ 323) P Value F-M (n ¼ 46) OGC (n ¼ 182) P Value
Age, median (IQR), yr 50 (18-74) 50 (19-72) .68 53 (19-71) 51 (18-74) .547 48 (19-79) 48 (18-70) .329 35 (19-50) 36 (18-50) .96
Age > 60 yr 33 (19) 111 (16.6) .498 15 (16.9) 64 (19.2) .76 18 (22.2) 43 (13.3) .056 0 0
Diagnosis .002 .941 .004 .234
AML 134 (77) 561 (84.1) 74 (83.1) 282 (84.4) 59 (72.8) 271 (83.9) 40 (87) 169 (92.9)
MDS/AML 29 (16.7) 96 (14.4) 14 (15.7) 49 (14.7) 14 (17.3) 45 (13.9) 5 (10.9) 12 (6.6)
MPN/AML 11 (6.3) 10 (1.5) 1 (1.1) 3 (.9) 8 (9.9) 7 (2.2) 1 (2.2) 1 (.5)
MRC cytogenetic risk .652 .592 .822 .64
Good 8 (4.6) 43 (6.4) 1 (1.1) 11 (3.3) 6 (7.4) 31 (9.6) 3 (6.5) 22 (12.1)
Intermediate 97 (55.7) 366 (54.9) 51 (57.3) 186 (55.7) 44 (54.3) 173 (53.6) 28 (60.9) 94 (51.6)
High 61 (35.1) 237 (35.5) 35 (39.3) 133 (39.8) 25 (30.9) 102 (31.6) 13 (28.3) 53 (29.1)
ELN classiﬁcation .90 .716 .927 .818
Favorable 14 (10.7) 65 (13.3) 4 (5.5) 24 (8.9) 9 (16.4) 40 (19) 6 (20) 26 (23.9)
Intermediate-I 23 (17.6) 83 (16.9) 17 (23.3) 55 (20.3) 6 (10.9) 25 (11.8) 5 (16.7) 12 (11)
Intermediate-II 39 (29.8) 145 (29.6) 19 (26) 80 (29.5) 19 (34.5) 63 (29.9) 8 (26.7) 27 (24.8)
Adverse 55 (42) 197 (40.2) 33 (45.2) 112 (41.3) 21 (38.2) 83 (39.3) 11 (36.7) 44 (40.4)
Treatment before HSCT
>1 Cycle of chemotherapy 173 (99.4) 660 (99) .776 18 (20.2) 109 (25.8) .789 80 (98.8) 318 (97.8) .495 45 (97.8) 180 (98.9) .413
Prior AlloHSCT 6 (3.4) 15 (2.4) .619 1 (1.1) 3 (.9) 1.0 5 (6.2) 13 (4.0) 1.0 3 (6.5) 6 (3.3) .39
Prior ASCT 2 (1.1) 6 (.7) .428 1 (1.1) 2 (.6) .509 1 (1.2) 3 (0.0) .376 0 0
Response before HSCT .479 1.0 .322 .075
CR1 89 (51.1) 334 (50) 89 (100) 334 (100) 0 0 0 0
CR2 28 (16) 101 (15.1) 0 0 24 (29.6) 101 (31.3) 19 (41.3) 61 (33.5)
CR3þ 4 (2.3) 5 (.8) 0 0 3 (4.9) 5 (1.5) 4 (8.7) 4 (2.2)
Active disease 53 (30.4) 227 (34) 0 0 53 (31.2) 207 (33.1) 23 (50) 117 (64.3)
RIC 10 (5.7) 43 (6.4) .862 3 (3.4) 16 (4.8) .775 7 (8.6) 25 (7.7) .818 0 8 (4.4) .364
Stem cell source .055 .007 .442 .866
Peripheral blood 130 (74.7) 424 (63.6) 72 (80.9) 219 (65.6) 54 (66.7) 199 (61.6) 28 (60.9) 114 (62.6)
Marrow 44 (25.3) 243 (36.4) 17 (19.1) 115 (34.4) 27 (33.3) 124 (38.4) 18 (39.1) 68 (37.4)
Donor .101 .001 .213 .74
MRD 114 (65.5) 339 (50.8) 62 (69.7) 168 (50.3) 49 (60.5) 168 (52) 26 (56.5) 108 (59.3)
MUD 60 (34.5) 328 (49.2) 27 (30.3) 166 (49.7) 32 (39.5) 155 (48) 20 (43.5) 74 (40.7)
Engraftment 167 (96) 651 (97.6) .397 85 (95.5) 326 (97.6) .166 79 (97.5) 315 (97.5) .738 46 (100) 179 (98.4) 1.0
Median time to ANC/platelet engraftment, d 12/13 12/13 1.0 12/13 12/14 .94 12/13 12/13 1.0 12/14 12/14 1.0
Day 30 donor chimerism .957 .370 .713 .706
Donor 92 (55.1) 361 (55.7) 42 (48.8) 166 (50.5) 49 (62.8) 191 (61.8) 33 (76.7) 113 (66.5)
Mixed 72 (43.1) 208 (41.1) 44 (51.2) 155 (47.1) 26 (33.3) 107 (34.6) 9 (20.9) 48 (28.2)
Autologous 0 1 (.2) 0 0 0 1 (.3) 0 1 (.6)
Final response .598 .881 .215 .211
CCR/CR 155 (92.3) 612 (92.9) 84 (97.7) 315 (95.7) 67 (85.9) 288 (90) 41 (91.1) 166 (91.7)
NR 9 (5.4) 38 (5.8) 1 (1.2) 9 (2.7) 8 (10.3) 28 (8.8) 2 (4.4) 13 (7.2)
ED 4 (2.4) 9 (1.4) 1 (1.2) 5 (1.5) 3 (3.8) 4 (1.2) 2 (4.4) 2 (1.1)
IQR indicates interquartile range; MDS/AML, acute myeloid leukemia arising frommyelodysplastic syndrome; MPN/AML, acute myeloid leukemia arising frommyeloproliferative neoplasm; MRC, The Medical Research Council;
ELN, European Leukemia Net; AlloHSCT, allogeneic hematopoietic stem cell transplantation, ASCT, autologous stem cell transplantation; MUD, matched unrelated donor; ANC, absolute neutrophil count; CCR, complete cy-
togenetic remission; NR, not in remission; ED, early death.
















Transplantation Outcomes of F-M and OGC Group Stratiﬁed by Remission Status before Transplantation


















1-Year CIR 34.1 41.3 .044 27.7 31.2 .419 39.8 52 .039 42.5 55.2 .045
1-Year NRM 23.2 15.7 .004 17.2 13.5 .258 29.1 17.4 .004 35.8 25.5 .141
Acute GVHD
All grades 51.1 50.4 .691 48.3 48.8 .479 54.3 52.3 .612 52.2 46.7 .701
Grade 2/4 28.2 28.3 1.0 16.9 27.5 .104 39.5 30.2 .186 32.6 25.5 .488
Grade 3/4 10.3 5.8 .042 4.5 3.9 .764 16 8 .036 17.4 7.7 .055
Chronic GVHD
All grade 44.3 37.8 .132 50.6 41 .418 38.3 34.7 .284 41.3 41.2 .266
Extensive 34.5 26.5 .047 37.1 27.5 .09 33.3 25.4 .162 39.1 31.1 .38
3-Year OS 43.4 44 .449 55.3 53.7 .706 32.8 34 .601 32.4 40.1 .21
3-Year PFS 40.3 38.3 .943 52.4 47.1 .984 29.7 29.2 .737 32.8 32.9 .956
Data presented are %, unless otherwise indicated.
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plantation in ﬁrst CR had comparable NRM (17.2% in F-M
group versus 13.5% in OGC group, P ¼ .258) (Supplemental
Figure 6). However, for patients younger than 50 years
beyond ﬁrst CR, the NRM was not signiﬁcantly different
(35.8% in F-M group versus 25.5% in OGC group, P ¼ .141)
(Figure 1B). These results suggest that this subgroup of
patients might beneﬁt from a gender-mismatched trans-
plantation (Table 2). Beside remission status, NRM of F-M
group was higher than in OGC group in subgroups of the
patients older than 50 years, having secondary AML, with
active disease before HSCT, receiving peripheral blood stem
cells, and with MRD. Interestingly, using gender- and race-Figure 1. (A) Shows CIR and (B) shows NRM of patients beyond ﬁrst CR
younger than 50 years.mismatched donor together did not inﬂuence the incidence
of NRM (Table 3). Factors associated with higher NRM
in univariate analyses were age, disease beyond ﬁrst CR
before transplantation, and the development of acute GVHD
(Table 4). All of these factors, as well as transplantation in
male patients using stem cells from female donors, retained
their prognostic signiﬁcance in multivariate analysis
(Table 5).
GVHD
Although the cumulative incidence of all grades acute
GVHD was comparable between the F-M (51.1%) and OGC
groups (50.4%), (P ¼ .691), the incidence of grade 3 and 4
acute GVHD was signiﬁcantly higher in the F-M group (10.3%
versus 5.8%, P ¼ .042). A higher incidence of severe acute
GVHD (grade 3 and 4) was also seen in patients beyond ﬁrst
CR before transplantation (16% in the F-M group versus 8% in
the OCG group, P ¼ .036). Moreover, in patients beyond ﬁrst
CR who were younger than 50 years, the cumulative inci-
dence of grades 3 and 4 acute GVHD had a trend to be higher
in F-M group (17.4% in the F-M group versus 7.7% in the OGC
group, P ¼ .055). A similar incidence of chronic GVHD all
grades was seen in both groups (44.3% in F-M group, 37.8% in
OGC group, P ¼ .132). However, a higher incidence of chronic
extensive GVHD was found in the F-M group than those in
the OGC group (34.5% versus 26.5%, P ¼ .047).
Survival
The beneﬁt of the GVL effect resulted in a lower relapse
rate in the F-M group. However, because of higher NRM
related primarily to higher incidences of acute GVHD grades
3 and 4 and chronic extensive GVHD, this beneﬁt did not
translate into superior survival compared with OGC group.
Three-year PFS of the entire cohort was 38.7%. There was no
signiﬁcant difference in PFS of F-M and OCG group (3-year
PFS 40.3% in the F-M group versus 38.3% in the OGC group;
P ¼ .943) (Supplemental Figure 7).
Three-year OS of thewhole cohort was 43.9%. Again, there
was no signiﬁcant difference in OS of the F-M and OGC
groups. Three-year OS was 43.4% in the F-M group versus
44% in the OGC group (P ¼ .449) (Table 2) (Supplemental
Figure 8). The similar PFS and OS of all donor-recipient
gender combinations were also seen in subgroup of the pa-
tients in ﬁrst CR or beyond ﬁrst CR. The PFS and OS were also
similar even for patients beyond ﬁrst CR younger than
50 years who had lower CIR and yet comparable NRM, which
means that the protection from relapse of F-M trans-
plantation was not strong enough to balance the risk of
Table 3
Transplantation Outcomes of F-M and OGC Group Stratiﬁed by Patient and Transplantation Characteristics
Factor 3-Year PFS 3-Year OS 1-Year CIR 1-Year NRM
F-M OGC P Value F-M OGC P Value F-M OGC P Value F-M OGC P Value
Age
< 50 Yr 42.7 40.9 .793 43.7 48.8 .208 34.1 41.7 .036 20.4 11.6 .243
 50 Yr 37.7 35.4 .693 43.4 38.6 .825 33.7 40.9 .215 26.1 17.7 .003
Race mismatched
Yes 47.6 46.5 .880 40 52.7 .904 30.6 34.4 .713 25 7.1 .758
No 44.8 39.3 .657 45.5 45.2 .603 34.2 42 .118 21.4 16.2 .066
Secondary AML
Yes 31 29.2 .873 37.1 30.6 .825 45.2 47.5 .808 33.4 23.1 .868
No 41.8 40.1 .972 43.8 46.9 .208 32.3 40.2 .084 19.9 14 .005
High-risk cytogenetics
Yes 37 33.2 .936 40.8 37.7 .866 46.8 48.3 .626 14.9 17.5 .326
No 37.5 44.6 .665 50 48.5 .797 12.5 24.6 .970 27.1 22.6 .505
ELN classiﬁcation
Favorable 49.8 42 .681 55.6 52.3 .757 23.2 26.8 0.549 25.3 27.3 .435
Intermediate-I 43.4 46.3 .557 49.5 51.8 .625 26.9 24.2 0.896 29.0 27.1 .487
Intermediate-II 45.3 47.7 .870 47.2 50.3 .451 30.2 26.5 0.384 24.4 22.4 .797
Adverse 27.3 29.4 .838 31.3 35.2 .365 45.2 41.3 0.496 26.3 25.1 .965
Active disease
Yes 29.8 19.9 .623 21.1 24.6 .575 50.3 60.7 .029 37.9 18.6 .002
No 52.5 47.5 .885 55.9 53.8 .786 25.7 32.5 .271 16.5 14 .201
Conditioning regimens
RIC 10 21.8 .392 20 22.8 .495 60 58 .816 34.4 22.3 .376
MAC 42.2 39.4 .823 44.9 45.5 .519 32.3 40.2 .045 23.7 16.6 .006
SC sources
Peripheral blood 43.4 37.2 .731 42.4 43.4 .258 32.8 40.9 .028 25.1 14.2 .003
Marrow 31.8 40.1 .650 46.5 44.8 .709 37.6 41.8 .938 21 17.6 .421
HSCT types
MRD 45.5 36.7 .230 46.2 43 .991 37.6 42.8 .005 22.1 14.3 .017
MUD 30.4 40.2 .128 38.5 45.4 .172 46.8 39.5 .486 25.3 16.5 .125
MAC indicates myeloablative conditioning; SC, stem cell.
Data presented are %, unless otherwise indicated.
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number of patients could have contributed to the failure to
identify a signiﬁcant difference in survival for this group.
Other factors associated with poor PFS in univariate
analyses were adverse ELN risk, disease beyond ﬁrst CR
before transplantation, use of a RIC regimen, and mixed
donor-recipient chimerism early after transplantation,
whereas chronic GVHD was associated with better PFS and
OS (Table 4). In multivariate analyses for PFS and OS, inde-
pendent prognostic factors for better outcomes were trans-
plantation in ﬁrst CR and the development of cGVHD,
whereas adverse ELN risk and the use of RIC had a negative
impact (Table 5).Table 4
Univariate Analyses for PFS, OS, RI, and NRM
Factors PFS OS
HR P Value HR
Age 1.084 .72 1.144
F-M 1.096 .945 1.044
Race mismatched 1.095 .155 1.095
Secondary AML 1.201 .08 1.18
High-risk cytogenetics 1.124 .201 1.12
Adverse ELN risk 1.669 <.001 1.756
Beyond ﬁrst CR 1.717 <.001 1.7
RIC 1.374 <.001 1.209
Marrow stem cells 1.05 .851 1.023
MUD 1.011 .906 1.006
Mixed chimerism 1.792 <.001 1.034
Acute GVHD 1.129 .501 1.097
Chronic GVHD .333 <.001 .475
RI indicates relapse incidence; HR, hazard ratio.DISCUSSION
In this study, we analyzed the impact of female donors to
male recipients in a large cohort of AML patients treatedwith
the same conditioning regimen at a single institution. To our
knowledge, this is the ﬁrst study conducted in a homoge-
neous group of patients with AML treated with the same
conditioning regimen to determine the impact of donor-
recipient gender matching on outcomes of hematopoietic
stem cell transplantation. Our results clearly demonstrated
that male patients with AML had a lower relapse rate
when they received a gender-mismatched transplant. These
beneﬁcial effects were, in general, offset by a higher
treatment-related mortality, related by a higher incidence of
GVHD and overall similar survival outcomes. These ﬁndingsRI NRM
P Value HR P Value HR P Value
.004 1.03 .059 1.215 .014
.467 .872 .041 1.279 .005
.194 .803 .452 1.641 .33
.12 1.263 .093 1.231 .225
.243 1.405 .004 1.485 .195
<.001 1.342 .031 1.1 .842
<.001 1.348 <.001 1.194 .027
<.001 1.469 <.001 .741 .339
.656 1.009 .855 .988 .884
.895 1.029 .602 1.028 .727
.496 1.105 .004 1.198 .309
.327 .836 .097 1.719 .001
<.001 .303 <.001 1.15 .451
Table 5
Multivariate Analyses for PFS, OS, RI, and NRM
Factor HR 95% CI P Value
Prognostic factors for PFS
Beyond ﬁrst CR .45 .38-.69 <.001
RIC 1.97 1.31-2.84 .001
Mixed chimerism 1.13 .94-1.62 .135
Chronic GVHD .64 .41-.84 <.001
Adverse ELN risk 1.71 1.37-2.13 <.001
Prognostic factors for OS
Age 1.01 .91-1.22 .331
Beyond ﬁrst CR .57 .46-.81 <.001
RIC 2.14 1.39-2.99 <.001
Chronic GVHD .55 .38-.79 .002
Adverse ELN risk 1.82 1.32-2.43 <.001
Prognostic factors for CIR
F-M .71 .47-.91 .04
High-risk cytogenetics 1.40 1.08-1.81 .01
RIC 1.92 1.25-2.95 .003
Beyond ﬁrst CR 2.48 1.35-2.68 <.001
Mixed chimerism 1.17 1.03-1.33 .015
Chronic GVHD .52 .35-.77 .001
Adverse ELN risk 1.27 1.11-1.45 .045
Prognostic factors for NRM
F-M 1.28 1.02-1.61 .031
Age 1.45 1.01-2.11 .048
Acute GVHD 1.65 1.18-2.30 <.001
Beyond ﬁrst CR 1.24 1.05-1.46 .009
CI indicates conﬁdence interval.
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beneﬁt from a female donor? Although younger male pa-
tients with advanced disease seem to beneﬁt the most from
transplantation with a female donor due to signiﬁcantly
lower relapse and comparable NRM, this did not translate
into improved survival, either.
The association between gender-mismatched trans-
plantation and risk of NRM has been reported in several
other studies [4,7,15,16]. In a retrospective European Group
for Blood and Marrow Transplantation analysis on patients
with leukemia (including 1405 patients with AML), the
authors showed that female donors to male recipients,
compared with OGC, signiﬁcantly inﬂuenced risk of NRM in
both AML and acute lymphoid leukemia (ALL) [15]. Later,
Randolph et al. retrospectively studied outcomes of 3238
patients with hematologic malignancies from the Fred
Hutchinson Cancer Center. In this study, the female to male
combinationwas associated with increased risk of death and
higher incidence of extensive chronic GVHD [4]. Overall, we
found that NRM was signiﬁcantly higher in the F-M group
compared with the OGC group, but only in patients beyond
ﬁrst CR, whereas NRM for patients who underwent trans-
plantation in ﬁrst CR was not different. This higher NRM in
the F-M group was paralleled by higher incidences of grades
3 and 4 acute GVHD as well as chronic extensive GVHD.
These ﬁndings suggests that mismatch in miHA located on
the Y chromosome might play an important role in the
pathogenesis of GVHD and results in increased NRM in F-M
transplantation. However, in multivariate analysis, we found
that both F-M transplantation and acute GVHD were inde-
pendent prognostic factors for NRM, with hazard ratios of
1.28 and 1.65, respectively. These results illustrate that there
is not a simple association between gendermismatch, GVHD,
and NRM. Therefore, factors that inﬂuence NRM in F-M
transplantation and the relationship with the development
of GVHD remain to be clariﬁed.
The miHA on the Y chromosome in male patients also
inﬂuence immune-mediated antitumor effects whenrecognized by T cells from female donors. Our study results
showed that transplantation with a female donor for male
recipients was associated with a lower relapse rate when
compared with OGC, which is consistent with the previous
report in chronic myeloid leukemia (CML) patients by Grat-
wohl et al. In this study, the authors found a decreased risk of
relapse in male patients who received grafts from female
donors compared with female recipients from female donors
[6].
Whether AML patients beneﬁt from reduction of relapse
rate in gender-mismatched transplantation, in particular F-M
gender combination, was unclear. In 2004, Randolph et al.
studied outcomes of 3238 patients who underwent alloge-
neic stem cell transplantation for various hematologic ma-
lignancies (including 1023 AML patients). This group found
that male patients with female donors had a lower risk for
relapse compared with all other donor-recipient gender
categories. However, a statistically signiﬁcant difference was
seen only in patients with CML, whereas patients with AML
and ALL had similar relapse rate in all donor-recipient gender
combinations [4]. Here, wewere able to show a lower relapse
rate associated with a female donor for male recipients in a
uniform cohort of AML patients. Furthermore, we found that
F-M transplantation was an independent prognostic factor
for lower relapse in multivariate analysis. These results
indicate that the beneﬁt of chromosome Y-dependent GVL
effect might need more time than the increased NRM from
acute GVHD. Overall, the beneﬁt of lower relapse rate with a
female donor for male recipient did not translate into sur-
vival advantage because of an increased risk of NRM.
Consequently, we tried to identify a group of patients who
might have a survival beneﬁt from a stronger GVL effect
using a female donor. Male patients younger than 50 years
with high-risk disease (who underwent transplantation
beyond ﬁrst complete remission) had a 13% lower risk of
relapse when a female donor was used. Survival of male
recipients with a female donor in our study was at least as
good as with a male donor. Nevertheless, our study results
are different from the previous report by Stern et al., who
compared transplantation outcomes of F-M and OGC in
53,988 patients with hematologic malignancies (including
3701 AML patients) from the European Group for Blood and
Marrow Transplantation. They found that NRM in F-M HSCT
was greater than protection from relapse, leading to a net
negative effect on OS (43.2% in F-M versus 46.7% in OGC,
P < .001). However, when the analyses were done for each
type of leukemia separately, the signiﬁcant difference was
seen in CML (48% versus 55.4%, P < .001) and a trend was
noted for patients with AML (44.4% versus 46.2%, P ¼ .07),
whereas OS of F-M and OGC were comparable in patients
with ALL (40.9% versus 41.9%, P ¼ .54) [16].
Our ﬁndings also raise other questions: with a diffe-
rent method of GVHD prevention, for example post-
transplantation cyclophosphamide, which could result in
better control of GVHD and a lower NRM, would a net
favorable effect in survival be obtained for the F-M combi-
nation? Furthermore, whether a gender mismatch donor
lymphocyte infusion is more effective to decrease relapse
rate remains unclear.
In conclusion, our results indicate a strong GVL effect
mediated by the minor H-Y antigens in patients with AML,
which could be exploited in the future. Younger male
patients with advanced disease could be considered for a
female donor, as the relapse rate appears signiﬁcantly better,
although, at least for now, outcomes are not signiﬁcantly
P. Kongtim et al. / Biol Blood Marrow Transplant 21 (2015) 713e719 719better. Such donor does not appear to be justiﬁed for patients
in remission at transplantation. Future larger registry stu-
dies with focus on AML patients are needed to conﬁrm
these ﬁndings, as this could inﬂuence donor selection.
Moreover, novel methods of GVHD prevention, such as post-
transplantation cyclophosphamide, may decrease the inci-
dence of acute and chronic GVHD and tilt the balance in favor
of lower relapse rate with a net effect on improved survival
for these patients.
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